Regulatory Submission

Iovance's NSCLC filing hinges on IOV-LUN-202 data still to come in 2026

Fast Track status for lifileucel in lung cancer puts a regulatory filing on the calendar, but the feeder trial's own completion date sits four years out.

By AppliedXLJuly 13, 2026Trial NCT04614103

Executive Summary

Iovance has guided toward a 2026 regulatory filing for its approved TIL cell therapy in a new lung cancer population, resting on data from a study whose own completion timeline runs years past that target.
The FDA has already granted a favorable review designation for this specific use, giving the sponsor's filing plan a documented regulatory anchor even before topline data are in hand.
No other program shares this cell therapy's mechanism in this lung cancer population, leaving the asset without a direct precedent to benchmark against; the nearest active studies rely on antibody and small-molecule mechanisms instead.
The sponsor's stated 2026 filing timeline sits well ahead of the feeder trial's own registered completion date, a divergence that will resolve only when topline data actually post.

The filing plan

Iovance disclosed in an August 2024 corporate update that it expects a possible sBLA for lifileucel in NSCLC in 2026, supported by topline data from IOV-LUN-202. The feeder trial is registered as NCT04614103, a Phase 2 study of autologous LN-145 (lifileucel) in metastatic NSCLC patients who have progressed on prior anti-PD-1 therapy and platinum-based chemotherapy. The study is not designated registrational in the registry, targets 170 patients, and remains in Recruiting status as of its most recent registry update. Iovance+1

Regulatory footing

The FDA pathway timeline for this program shows a Fast Track designation granted May 7, 2026, specifically for lifileucel in previously treated, metastatic non-squamous NSCLC, ahead of the topline data readout the filing depends on. That designation permits rolling review and more frequent FDA engagement once an application is ready. The same regulatory timeline lists a subsequent step: Iovance has said data from the IOV-LUN-202 registrational Phase 2 trial could support a potential accelerated U.S. approval for lifileucel in NSCLC in 2027, with company commentary pointing to a possible launch in the second half of that year.

The timeline gap

NCT04614103's own registry history complicates the 2026 filing target. The trial's primary completion date moved from December 2022 to June 2024 in June 2022, then moved again to December 2030 in May 2024. Enrollment target rose from 95 to 170 patients in October 2023. A trial with a registered primary completion date six years past the sponsor's stated filing year can still support an interim topline readout ahead of full completion, but the registry itself does not carry that interim data cut. NCT04614103

Competitive position

No competitor shares lifileucel's TIL cell-therapy modality and mechanism in this NSCLC population; the closest cell-therapy precedent identified operates in a different tumor type and against a different target. The active NSCLC field surrounding this trial is built on PD-1 and PD-L1 antibodies (pembrolizumab, nivolumab, durvalumab, cemiplimab), EGFR and KRAS-directed small molecules (osimertinib, calderasib), and other non-cell-therapy mechanisms. Given that no validated cell-therapy mechanism has yet demonstrated a registrational-quality result in this post-anti-PD-1 NSCLC setting, a response-rate result from IOV-LUN-202 that clears a level informative enough to support accelerated approval, and that holds up on the confirmatory requirements that typically accompany that pathway, would be the result that distinguishes this program from the antibody- and small-molecule-driven field around it.

Sponsor track record

Iovance has one prior FDA approval on record, for lifileucel (marketed as Amtagvi) in previously treated advanced melanoma, which launched commercially in February 2024. Across its broader pipeline, the sponsor has completed three of four trials with one termination, a small base that limits any read on execution reliability. The company's own August 2024 disclosure emphasized commercial momentum for the melanoma indication as a reason for confidence in expanding the platform, a claim that speaks to manufacturing and commercial infrastructure but not to the NSCLC trial's own clinical result. Iovance

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.